Verastem, Inc.
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated prot…
Biotechnology
US, Needham [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Verastem, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2018 | -21.1800 | -18.580 | 0 | 28 | -67 | -409 | -66 | -14 | -68 | -14 | 21 | 164 |
| 2019 | -12.5400 | -23.790 | 26 | 16 | -72 | -524 | -65 | -8 | -94 | -8 | 77 | 94 |
| 2020 | -27.2200 | -4.860 | 17 | 54 | -169 | -107 | -126 | -27 | -132 | -27 | 101 | 315 |
| 2021 | -5.3000 | -4.760 | 88 | 1 | -67 | -104 | -50 | 0.75 | -49 | 0.75 | 62 | 8 |
| 2022 | -5.5800 | -4.711 | 2 | 2 | -81 | -103 | -61 | -1 | -61 | -1 | 24 | 15 |
| 2023 | -4.5800 | -3.144 | 2 | 5 | -73 | -69 | -71 | -3 | -73 | -3 | 24 | 34 |
| 2024 | -3.9600 | -3.004 | 0 | 8 | -87 | -65 | -83 | -4 | -92 | -4 | 30 | 51 |
| 2025 | - | -2.553 | - | 23 | - | -56 | - | -11 | - | -11 | - | 132 |
| 2026 | - | 2.F8X/td> | - | 2.F8X/td> | - | 2.F8X/td> | - | 2.F81/td> | - | 2.F81 | - | 2.F81 |
| 2027 | - | 1.F9X/td> | - | 1.F9X/td> | - | 1.F9X/td> | - | 1.F91/td> | - | 1.F91 | - | 1.F91 |
| 2028 | - | 0.F10X/td> | - | 0.F10X/td> | - | 0.F10X/td> | - | 0.F101/td> | - | 0.F101 | - | 0.F101 |